Ticker brief
EDIT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
4
crowd 14d
·
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-08 → 2026-10-09 · now +0.00 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.00 |
| @CrweWorld | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.25 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-09 | @OzmosiHealth | +0.00 | Editas plans Phase 1 hyperlipidemia results for EDIT-401 by year-end 2027. | · | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.00 | Editas scheduled Phase 0 hyperlipidemia results for EDIT-401 on Nov. 8. | · | tweet ↗ |
| 2026-10-08 | @OpenOutcrier | +0.25 | Recaps positive and negative broker comments on three stocks. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.50 | Biotech roundup reports acquisition, trial approval, study and financing events. | · | tweet ↗ |
| 2026-10-08 | @CrweWorld | +0.50 | Reports approval for Editas to initiate a first-in-human EDIT-401 clinical trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.